Physician profile
Jyming Wang
NPI 1851456669
$2,187.91
in general payments reported to CMS, 2019-2025
20 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $125 · 2021: $317 · 2022: $257 · 2023: $374 · 2024: $360 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $431.49 | 2023-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $268.59 | 2019-2023 | Steglatro |
| Janssen Pharmaceuticals, INC | $224.80 | 2019 | |
| Glaxosmithkline, LLC. | $221.93 | 2019-2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $149.94 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $147.49 | 2025 | Voquezna |
| Amarin Pharma, INC. | $141.83 | 2019-2022 | |
| Lilly USA, LLC | $120.10 | 2022-2024 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.66 | 2020-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $96.30 | 2019-2024 | Zoryve |
| Novo Nordisk INC | $56.74 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.81 | 2022 | |
| Rigel Pharmaceuticals, INC. | $43.55 | 2021-2022 | |
| Gilead Sciences, INC. | $27.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $20.14 | 2021 | |
| Agios Pharmaceuticals, INC. | $19.59 | 2025 | Pyrukynd |
| Esperion Therapeutics, INC. | $17.24 | 2021 | |
| Tempus Ai, INC | $15.06 | 2025 | Xt Cdx |
| Amgen INC. | $14.39 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyming Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.